|
1
|
Harris NL, Jaffe ES, Stein H, Banks PM,
Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter
KC, et al: A revised European-American classification of lymphoid
neoplasms: A proposal from the International Lymphoma Study Group.
Blood. 84:1361–1392. 1994.PubMed/NCBI
|
|
2
|
Steven H: Swerdlow IAfRoC, World Health
Organization: WHO classification of tumours of haematopoietic and
lymphoid tissues. International Agency for Research on Cancer.
2008.
|
|
3
|
No authors listed: A clinical evaluation
of the international lymphoma study group classification of
non-Hodgkin's lymphoma. The non-hodgkin's lymphoma classification
project. Blood. 89:3909–3918. 1997.PubMed/NCBI
|
|
4
|
Zhu YJ, Huang JJ, Xia Y, Zhao W, Jiang WQ,
Lin TY, Huang HQ and Li ZM: Primary mediastinal large B-cell
lymphoma (PMLBCL) in Chinese patients: Clinical characteristics and
prognostic factors. Int J Hematol. 94:178–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu LM, Fang H, Wang WH, et al: Prognostic
significance of rituximab and radiotherapy for patients with
primary mediastinal large B-cell lymphoma receiving
doxorubicin-containing chemotherapy. Leuk Lymphoma. 54:1684–1690.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Massoud M, Koscielny S, Lapusan S, Bosq J
and Ribrag V: Primary mediastinal large B-cell lymphomas treated
with dose-intensified CHOP alone or CHOP combined with
radiotherapy. Leuk Lymphoma. 49:1510–1515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hamlin PA, Portlock CS, Straus DJ, et al:
Primary mediastinal large B-cell lymphoma: Optimal therapy and
prognostic factor analysis in 141 consecutive patients treated at
Memorial Sloan Kettering from 1980 to 1999. Br J Haematol.
130:691–699. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Todeschini G, Secchi S, Morra E, et al:
Primary mediastinal large B-cell lymphoma (PMLBCL): Long-term
results from a retrospective multicentre Italian experience in 138
patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer.
90:372–376. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zinzani PL, Martelli M, Bertini M, et al:
Induction chemotherapy strategies for primary mediastinal large
B-cell lymphoma with sclerosis: A retrospective multinational study
on 426 previously untreated patients. Haematologica. 87:1258–1264.
2002.PubMed/NCBI
|
|
10
|
De Sanctis V, Finolezzi E, Osti MF, et al:
MACOP-B and involved-field radiotherapy is an effective and safe
therapy for primary mediastinal large B cell lymphoma. Int J Radiat
Oncol Biol Phys. 72:1154–1160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sehn LH, Donaldson J, Chhanabhai M, et al:
Introduction of combined CHOP plus rituximab therapy dramatically
improved outcome of diffuse large B-cell lymphoma in British
Columbia. J Clin Oncol. 23:5027–5033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pfreundschuh M, Trümper L, Osterborg A, et
al: CHOP-like chemotherapy plus rituximab vs. CHOP-like
chemotherapy alone in young patients with good-prognosis diffuse
large-B-cell lymphoma: A randomised controlled trial by the
MabThera International Trial (MInT) Group. Lancet Oncol. 7:379–391.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson PWM and Davies AJ: Primary
mediastinal B-cell lymphoma. Hematology/the Education Program of
the American Society of Hematology. Hematology Am Soc Hematol Educ
Program. 2008:349–358. 2008. View Article : Google Scholar
|
|
14
|
Rieger M, Osterborg A, Pettengell R, White
D, Gill D, Walewski J, Kuhnt E, Loeffler M, Pfreundschuh M and Ho
AD: Mab Thera International Trial (MInT) Group: Primary mediastinal
B-cell lymphoma treated with CHOP-like chemotherapy with or without
rituximab: Results of the Mabthera International Trial Group study.
Ann Oncol. 22:664–670. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vassilakopoulos TP, Pangalis GA,
Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala
A, Vrakidou E, Repoussis P, Poziopoulos C, et al: Rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone with or
without radiotherapy in primary mediastinal large B-cell lymphoma:
The emerging standard of care. Oncologist. 17:239–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
17
|
No authors listed: A predictive model for
aggressive non-hodgkin's lymphoma. The international non-hodgkin's
lymphoma prognostic factors project. N Engl J Med. 329:987–994.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Juweid ME, Wiseman GA, Vose JM, Ritchie
JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM,
Stolpen A, et al: Response assessment of aggressive non-Hodgkin's
lymphoma by integrated International Workshop Criteria and
fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin
Oncol. 23:4652–4661. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cheson BD, Pfistner B, Juweid ME, Gascoyne
RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca
E, et al: Revised response criteria for malignant lymphoma. J Clin
Oncol. 25:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mazzarotto R, Boso C, Vianello F, Aversa
MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D
and Sotti G: Primary mediastinal large B-cell lymphoma: results of
intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved
field radiotherapy on 53 patients. A single institution experience.
Int J Radiat Oncol Biol Phys. 68:823–829. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Savage KJ, Al-Rajhi N, Voss N, Paltiel C,
Klasa R, Gascoyne RD and Connors JM: Favorable outcome of primary
mediastinal large B-cell lymphoma in a single institution: The
British Columbia experience. Ann Oncol. 17:123–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zinzani PL, Stefoni V, Finolezzi E,
Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli
A and Martelli M: Rituximab combined with MACOP-B or VACOP-B and
radiation therapy in primary mediastinal large B-cell lymphoma: A
retrospective study. Clin Lymphoma Myeloma. 9:381–385. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Avigdor A, Sirotkin T, Kedmi M, Ribakovsy
E, Berkowicz M, Davidovitz Y, Kneller A, Merkel D, Volchek Y,
Davidson T, et al: The impact of R-VACOP-B and interim FDG-PET/CT
on outcome in primary mediastinal large B cell lymphoma. Ann
Hematol. 93:1297–1304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filippi AR, Piva C, Giunta F, Bellò M,
Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo
U, et al: Radiation therapy in primary mediastinal B-cell lymphoma
with positron emission tomography positivity after rituximab
chemotherapy. Int J Radiat Oncol Biol Phys. 87:311–316. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soumerai JD, Hellmann MD, Feng Y, Sohani
AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP and
Abramson JS: Treatment of primary mediastinal B-cell lymphoma with
rituximab, cyclophosphamide, doxorubicin, vincristine and
prednisone is associated with a high rate of primary refractory
disease. Leuk Lymphoma. 55:538–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunleavy K, Pittaluga S, Maeda LS, Advani
R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, et
al: Dose-adjusted EPOCH-rituximab therapy in primary mediastinal
B-cell lymphoma. N Engl J Med. 368:1408–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
